ANAVEX LIFE SCIENCES CORP.
AVXL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AVXL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for central nervous system (CNS) disorders, with lead candidates ANAVEX 2-73 and ANAVEX 3-71.
Key risk: Clinical and regulatory uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 6 clinical trials for ANAVEX LIFE SCIENCES CORP..
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for central nervous system (CNS) disorders, with lead candidates ANAVEX 2-73 and ANAVEX 3-71.
- Cash and cash equivalents were $118.3 million as of June 30, 2025 [sec].
- Net income was $7.8 million for the quarter ended June 30, 2025 [sec].
- Shareholders' equity was $94.9 million as of June 30, 2025 [sec].
- The company is advancing clinical trials for ANAVEX 2-73 and ANAVEX 3-71 [sec_mda · as of 2025-08-12].
- Net loss for the nine months ended June 30, 2025 was $36.6 million, compared to $31.4 million in the same period of 2024 [sec_mda · as of 2025-08-12].
What works
- Cash position of $118.3 million as of June 30, 2025 provides a multi-year runway to advance clinical programs [sec].
- Positive net income of $7.8 million in the latest quarter suggests improving financial trajectory [sec].
- Lead candidates have received FDA Fast Track and orphan drug designations, potentially accelerating development and regulatory review [sec_mda · as of 2026-02-09].
What to weigh
- Net loss for the nine months ended June 30, 2025 increased to $36.6 million from $31.4 million year-over-year, reflecting rising operating expenses [sec_mda · as of 2025-08-12].
- Cash used in operating activities was $30.4 million in the first nine months of fiscal 2025, up from $24.2 million in the prior-year period [sec_mda · as of 2025-08-12].
- The company has no approved products and its future revenue depends on successful clinical development and regulatory approval, which are uncertain [sec_mda · as of 2026-08-28].
From the filings
Quoted directly from source documents.
Net loss for the nine months ended June 30, 2025
“Net loss for the nine-months ended June 30, 2025, was $36.6 million”
SEC MD&A · August 12, 2025
Risks & what to watch (3)›
Key risks
- Clinical and regulatory uncertainty — No approved products; future revenue depends on successful clinical trials and regulatory approvals, which are inherently uncertain [sec_mda · as of 2026-08-28].
- Rising operating cash burn — Cash used in operations increased to $30.4M in 9 months ended June 2025 from $24.2M a year earlier [sec_mda · as of 2025-08-12].
- Dependence on financing — Company may need additional capital to fund operations if clinical timelines extend or costs exceed projections [sec_mda · as of 2026-08-28].
What to watch
- Regulatory decisions from FDA and EMA on ANAVEX 2-73 and ANAVEX 3-71, including potential Marketing Authorization Application outcome [sec_mda · as of 2026-02-09].
- Clinical trial data readouts for lead candidates, which will inform efficacy and safety profiles [sec_mda · as of 2025-08-12].
- Cash burn rate and any changes in operating expenses or financing activities [sec_mda · as of 2025-08-12].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run ANAVEX LIFE SCIENCES CORP. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ANAVEX LIFE SCIENCES CORP. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
39.0 months
D/E 0.07 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
191
Total value held
$135.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 7,727,900 | $23.7M |
| blackrock, inc. | 7,609,618 | $23.4M |
| state street corp | 4,512,028 | $13.9M |
| two sigma investments, lp | 3,247,888 | $10.0M |
| geode capital management, llc | 2,188,275 | $6.7M |
| susquehanna international group, llp | 1,539,563 | $4.7M |
| citadel advisors llc | 1,172,035 | $3.6M |
| bank of america corp /de/ | 863,150 | $2.6M |
| goldman sachs group inc | 804,435 | $2.5M |
| vanguard portfolio management llc | 783,148 | $2.4M |
Showing top 10 of 191 institutional holders of ANAVEX LIFE SCIENCES CORP.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 21.4%
- Days to cover
- 18.4
- Shares short
- 19,011,626
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AVXL short interestGovernance
Frequently asked questions
What is the AI investment thesis for ANAVEX LIFE SCIENCES CORP.?
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for central nervous system (CNS) disorders, with lead candidates ANAVEX 2-73 and ANAVEX 3-71.
Who is the CEO of ANAVEX LIFE SCIENCES CORP.?
Dr. Terrie Kellmeyer Ph.D. is the chief executive officer of ANAVEX LIFE SCIENCES CORP. (AVXL).
Where is ANAVEX LIFE SCIENCES CORP. headquartered?
ANAVEX LIFE SCIENCES CORP. (AVXL) is headquartered in New York, NY, United States.
What therapeutic areas does ANAVEX LIFE SCIENCES CORP. focus on?
ANAVEX LIFE SCIENCES CORP. develops therapies across Rare Disease, Neurology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.